Genmab A+s

Biontech Se

Ganmab A/s

Kristel Kemper

David Satijn

Esther C W Breij

Dennis Verzijl

Paul Parren

Edward Norbert Van Den Brink

Rik Rademaker

Patrick Engelberts

Bart E C G De Goeij

Sjeng Horbach

Ugur Sahin

Simone Oostindie

Sina Fellermeier-kopf

Lars Guelen

Maarten Van Der Kroef

Maren Köhne

Pauline Linda De Goeje

Andrea Gorlani

Farshid Alemdehy

The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

Antibodies capable of binding to OX40, variants thereof and uses thereof

The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

Antibodies

The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.

Antibodies binding to CD30 and CD3

Growing community of inventors

Utrecht, Netherlands

Kristel Kemper